These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28389452)

  • 1. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
    Spooner LM; Abraham GM
    Am J Health Syst Pharm; 2017 Apr; 74(8):555. PubMed ID: 28389452
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
    Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
    Nguyen THT; Guedj J; Uprichard SL; Kohli A; Kottilil S; Perelson AS
    Sci Rep; 2017 Aug; 7(1):10233. PubMed ID: 28860456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
    Brochot E; Bodeau S; Duverlie G
    Ther Drug Monit; 2015 Aug; 37(4):550-1. PubMed ID: 25525764
    [No Abstract]   [Full Text] [Related]  

  • 10. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports.
    Saleem K; Wahid B; Ali A; Rafique S; Naz Z; Usman S; Idrees M
    Viral Immunol; 2018; 31(6):480-483. PubMed ID: 29694794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    He QF; Zhang QF; Zhang DZ
    Dig Dis Sci; 2016 Nov; 61(11):3108-3117. PubMed ID: 27619394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.
    Barocas JA; Beiser M; León C; Gaeta JM; O'Connell JJ; Linas BP
    JAMA Intern Med; 2017 Jun; 177(6):880-882. PubMed ID: 28395004
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.
    Rezaee-Zavareh MS; Hesamizadeh K; Behnava B; Alavian SM; Gholami-Fesharaki M; Sharafi H
    Ann Hepatol; 2017; 16(2):188-197. PubMed ID: 28233739
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Nagral A; Jhaveri A; Sawant S; Parikh NS; Nagral N; Merchant R; Gandhi M
    Indian J Pediatr; 2019 Feb; 86(2):148-153. PubMed ID: 30097845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.